PMID- 31844635
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 2328-8957 (Print)
IS  - 2328-8957 (Electronic)
IS  - 2328-8957 (Linking)
VI  - 6
IP  - 11
DP  - 2019 Nov
TI  - The CHROME Study, a Real-world Experience of Single- and Multiple-Dose 
      Oritavancin for Treatment of Gram-Positive Infections.
PG  - ofz479
LID - 10.1093/ofid/ofz479 [doi]
LID - ofz479
AB  - BACKGROUND: Oritavancin (ORI) is a long-acting lipoglycopeptide indicated for the 
      treatment of adult patients with acute bacterial skin and skin structure 
      infections (ABSSSIs) caused or suspected to be caused by susceptible 
      Gram-positive (GP) pathogens. METHODS: Data collected from a retrospective 
      observational program (2014-2017), Clinical and Historic Registry and Orbactiv 
      Medical Evaluation (CHROME), describe the utilization, outcomes, and adverse 
      events (AEs) associated with ORI in 440 patients treated at 26 US sites for 
      ABSSSI and other GP infections. RESULTS: Clinical success in evaluable patients 
      receiving at least 1 dose of oritavancin was 88.1% (386/438). In a subgroup of 
      patients who received ORI for skin and soft tissue infections (n = 401) and 
      bacteremia (n = 7), clinical success was achieved in 89.0% and 100%, 
      respectively. A cohort of 32 patients received 2-10 ORI doses separated by no 
      more than 14 days for complicated GP infections. Clinical success was observed in 
      30 of 32 patients (93.8%), including 10 of 11 (90.9%) patients with bone and 
      joint infections and 7 of 8 (87.5%) patients with osteomyelitis. In the safety 
      evaluable population, the overall rate of AEs was 6.6%. CONCLUSIONS: We describe 
      results from a real-world program that includes the largest multicenter, 
      retrospective, observational study in patients who received at least 1 dose of 
      ORI for the treatment of GP infections. This study confirms that ORI is an 
      effective, well-tolerated antibiotic used in single and multiple doses for the 
      treatment of ABSSSIs and complicated GP infections.
CI  - (c) The Author(s) 2019. Published by Oxford University Press on behalf of 
      Infectious Diseases Society of America.
FAU - Redell, Mark
AU  - Redell M
AD  - Melinta Therapeutics, Morristown, New Jersey, USA.
FAU - Sierra-Hoffman, Miguel
AU  - Sierra-Hoffman M
AD  - Director of Research, Texas A&M affiliated Detar Family Medicine Program & 
      College of Medicine, Victoria, Texas, USA.
AD  - Texas A&M University, Bryan, Texas, USA.
FAU - Assi, Maha
AU  - Assi M
AD  - IDC Clinical Research, Wichita, Kansas, USA.
FAU - Bochan, Markian
AU  - Bochan M
AD  - Infectious Diseases of Indiana, Indianapolis, Indiana, USA.
FAU - Chansolme, David
AU  - Chansolme D
AD  - Infectious Disease Consultants of Oklahoma City, Oklahoma City, Oklahoma, USA.
FAU - Gandhi, Anurag
AU  - Gandhi A
AD  - Birmingham Infectious Disease and Infusion, Birmingham, Alabama, USA.
FAU - Sheridan, Kathleen
AU  - Sheridan K
AD  - University of Pittsburgh Physicians, Pittsburgh, Pennsylvania, USA.
FAU - Soosaipillai, Ivan
AU  - Soosaipillai I
AD  - Infectious Disease Associates of North Central Florida, Ocala, Florida, USA.
FAU - Walsh, Thomas
AU  - Walsh T
AD  - Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
FAU - Massey, Jill
AU  - Massey J
AD  - Melinta Therapeutics, Morristown, New Jersey, USA.
LA  - eng
PT  - Journal Article
DEP - 20191104
PL  - United States
TA  - Open Forum Infect Dis
JT  - Open forum infectious diseases
JID - 101637045
PMC - PMC6903788
OTO - NOTNLM
OT  - ABSSSI
OT  - oritavancin
OT  - real-world experience
OT  - registry
OT  - skin infections
EDAT- 2019/12/18 06:00
MHDA- 2019/12/18 06:01
PMCR- 2019/11/04
CRDT- 2019/12/18 06:00
PHST- 2019/08/15 00:00 [received]
PHST- 2019/11/01 00:00 [accepted]
PHST- 2019/12/18 06:00 [entrez]
PHST- 2019/12/18 06:00 [pubmed]
PHST- 2019/12/18 06:01 [medline]
PHST- 2019/11/04 00:00 [pmc-release]
AID - ofz479 [pii]
AID - 10.1093/ofid/ofz479 [doi]
PST - epublish
SO  - Open Forum Infect Dis. 2019 Nov 4;6(11):ofz479. doi: 10.1093/ofid/ofz479. 
      eCollection 2019 Nov.